Cardiol Therapeutics (CRDL) vs Organogenesis (ORGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Organogenesis (ORGO) over the past year, gaining 24.5% versus a loss of 68.1%. Over five years, CRDL leads with a -66.4% price change compared with -87.9% for ORGO. Organogenesis is the larger company by market cap ($164.1 million vs $157.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | ORGO |
|---|---|---|
| Share price | $1.30 | $1.28 |
| Market cap | $157.36M | $164.06M |
| 1-day change | -1.89% | -3.41% |
| YTD return | +38.36% | -74.52% |
| 1-year return | +24.53% | -68.12% |
| 5-year return | -66.41% | -87.95% |
| EPS (TTM) | $-0.25 | $-0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $7.08 |
| 52-week low | $0.88 | $1.25 |
| Distance from 52-week high | -44.66% | -81.98% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +545.56% | +56.86% |
| Average volume | 1.44M | 772.95K |
| Shares outstanding | 121.51M | 128.67M |
| Employees | 18 | 854 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed ORGO by 92.6 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Organogenesis
ORGO stock →Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees
CRDL vs ORGO FAQ
Which is bigger, Cardiol Therapeutics or Organogenesis?
Organogenesis (ORGO) is larger, with a market capitalization of $164.06M compared with $157.36M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, CRDL or ORGO?
CRDL returned +24.53% over the past 12 months, compared with -68.12% for ORGO (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Organogenesis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cardiol Therapeutics and Biotechnology: Pharmaceutical Preparations for Organogenesis.